Carisma Announces Latest Data From Phase 1 Clinical Trial Of CT-0508 At 8th Annual CAR-TCR Summit
Portfolio Pulse from Happy Mohamed
Carisma Therapeutics Inc. (NASDAQ:CARM) has announced the latest data from its Phase 1 clinical trial of CT-0508, a treatment for advanced/metastatic HER2 overexpressing cancers. The data supports the primary safety and feasibility endpoints of single-day bolus dosing of CT-0508. The company will present these findings at the 8th Annual CAR-TCR Summit. The trial is led by Kim A. Reiss, MD, and the data was presented by Michael Klichinsky, PharmD, PhD, Co-Founder and Chief Scientific Officer at Carisma.
September 01, 2023 | 12:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Carisma Therapeutics' positive data from the Phase 1 clinical trial of CT-0508 supports the safety and feasibility of the treatment. This could potentially boost investor confidence in the company's innovative immunotherapies.
The positive data from the Phase 1 clinical trial of CT-0508 supports the safety and feasibility of the treatment. This could potentially boost investor confidence in the company's innovative immunotherapies, leading to a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100